Key Highlights

  • LFWD reported Q3 Revenue of US$5,428 thousand versus US$6,195 thousand a year earlier.
  • Net loss was US$5,052 thousand, or US$1.32 per share, versus US$3,170 thousand.
  • Gross Margin was 27.4% versus 43.7% in the prior-year quarter.
  • Cash and cash equivalents were US$4.5 million at September 30, 2026.

LFWD filed its Quarterly Report on November 13, 2026, for the three and nine months ended September 30, 2026. Revenue was US$5,428 thousand, versus US$6,195 thousand, a decrease of 12%. The company said the decrease reflected lower ReWalk revenue of US$1.3 million, primarily from lower sales in Europe and the United States, including the near-term effect of moving ReWalk from a direct-sales model to a channel-partner distribution model, partly offset by approximately US$0.5 million of higher AlterG revenue.

Gross profit was US$1,487 thousand, or 27.4% of revenue, versus US$2,707 thousand, or 43.7%. The company attributed the lower margin primarily to adverse foreign Exchange Rate fluctuations, revenue sharing expense, higher freight costs and tariffs. For the nine months, revenue was US$15,974 thousand versus US$16,953 thousand, and Gross Profit was US$5,538 thousand, or 34.7% of revenue, versus US$7,340 thousand, or 43.3%.

Operating Expenses and Net Loss

Research and development expenses, net, were US$1,941 thousand versus US$721 thousand. The company tied the increase primarily to approximately US$0.5 million of clinical trial and CRO costs for the Oratech clinical trial, together with higher AlterG project costs and development activities for the Skelable technology following its acquisition. Sales and Marketing expenses were US$3,351 thousand versus US$3,168 thousand, which the company tied to trade shows and digital marketing. General and administrative expenses were US$2,165 thousand versus US$1,958 thousand.

Total operating expenses were US$7,457 thousand versus US$5,847 thousand, and the operating loss was US$(5,970) thousand versus US$(3,140) thousand. Financial income, net, was US$926 thousand versus financial expense of US$23 thousand. Net loss was US$(5,052) thousand, or US$(1.32) per share, versus US$(3,170) thousand, or US$(2.37). Per-share figures reflect a one-for-twelve reverse share split effective February 24, 2026.

For the nine months, Research and Development expenses, net, were US$9,540 thousand versus US$2,406 thousand, including a one-time acquired in-process research and development charge of approximately US$4.9 million upon completion of the Oratech acquisition. Net loss was US$(27,364) thousand, or US$(9.91) per share, versus US$(14,566) thousand, or US$(13.87).

Liquidity and Going Concern Disclosure

Cash and cash equivalents were US$4.5 million at September 30, and the accumulated Deficit was US$312.1 million. The company stated that these factors raise substantial doubt about its ability to continue as a going concern, and that its existing cash resources are not expected to be sufficient to fund its anticipated operating requirements for the next twelve months. It reported approximately US$10.7 million of noncancelable purchase commitments, nearly all payable within twelve months.

The company said it intends to fund operations through cash on hand, measures to reduce operating cash expenditures, and potential issuances of Equity and Debt securities, cash exercises of warrants, or arrangements with strategic partners, and that it cannot assure that financing is available.

Quarter in Review: Product Lines, Costs and Funding Needs

LFWD's third quarter combined lower ReWalk revenue, higher AlterG revenue, a lower gross margin and higher research spending. Revenues come from the sale of ReWalk, AlterG, ReStore and MyoCycle systems, extended warranties and repair services. The company said it expects growth to be primarily driven by ReWalk Personal sales through expanded reimbursement coverage and channel partnerships, and by AlterG Anti-Gravity system shipments.